Home
About
Overview
Sharing Data
ORCID
Help
History (1)
TBK1 inhibition unleashes RIPK1, resensitizing tumors to immunotherapy.
See All Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
TBK1 inhibition unleashes RIPK1, resensitizing tumors to immunotherapy.
Kelliher MA, Fitzgerald KA. TBK1 inhibition unleashes RIPK1, resensitizing tumors to immunotherapy. Trends Immunol. 2023 03; 44(3):156-158.
View in:
PubMed
subject areas
Cell Death
Humans
Immunotherapy
Neoplasms
Receptor-Interacting Protein Serine-Threonine Kinases
authors with profiles
Michelle A Kelliher PhD
Katherine A Fitzgerald PhD